These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 36623777)
1. Real-World Implications of the American Gastroenterology Association Nonalcoholic Fatty Liver Disease Clinical Care Pathway in the US Adult Population. Xu X; Alanaeme J; Wen Y; Colantonio LD; Muntner P; Long MT Gastroenterology; 2023 Apr; 164(4):688-689.e4. PubMed ID: 36623777 [No Abstract] [Full Text] [Related]
2. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Kanwal F; Shubrook JH; Adams LA; Pfotenhauer K; Wai-Sun Wong V; Wright E; Abdelmalek MF; Harrison SA; Loomba R; Mantzoros CS; Bugianesi E; Eckel RH; Kaplan LM; El-Serag HB; Cusi K Gastroenterology; 2021 Nov; 161(5):1657-1669. PubMed ID: 34602251 [TBL] [Abstract][Full Text] [Related]
3. Updated S2k Clinical Practice Guideline on Non-alcoholic Fatty Liver Disease (NAFLD) issued by the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) - April 2022 - AWMF Registration No.: 021-025. ; Z Gastroenterol; 2022 Sep; 60(9):e733-e801. PubMed ID: 36100201 [No Abstract] [Full Text] [Related]
4. NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). Vos MB; Abrams SH; Barlow SE; Caprio S; Daniels SR; Kohli R; Mouzaki M; Sathya P; Schwimmer JB; Sundaram SS; Xanthakos SA J Pediatr Gastroenterol Nutr; 2017 Feb; 64(2):319-334. PubMed ID: 28107283 [TBL] [Abstract][Full Text] [Related]
8. Clinical Care Pathway for the Risk Stratification and Management of Patients With Non-alcoholic Fatty Liver Disease. Sullivan S; Jirapinyo P; Kumbhari V Gastroenterology; 2022 Jun; 162(7):2131-2132. PubMed ID: 35032500 [No Abstract] [Full Text] [Related]
9. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Chalasani N; Younossi Z; Lavine JE; Charlton M; Cusi K; Rinella M; Harrison SA; Brunt EM; Sanyal AJ Hepatology; 2018 Jan; 67(1):328-357. PubMed ID: 28714183 [No Abstract] [Full Text] [Related]
10. Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review. Schattenberg JM; Anstee QM; Caussy C; Bugianesi E; Popovic B Expert Rev Gastroenterol Hepatol; 2021 Nov; 15(11):1253-1266. PubMed ID: 34493137 [TBL] [Abstract][Full Text] [Related]
11. Reply to: Correspondence on "The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease". Xu X; Nan Y J Hepatol; 2022 Feb; 76(2):484-485. PubMed ID: 34774637 [No Abstract] [Full Text] [Related]
12. Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Spengler EK; Loomba R Mayo Clin Proc; 2015 Sep; 90(9):1233-46. PubMed ID: 26219858 [TBL] [Abstract][Full Text] [Related]
13. Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments. Roeb E; Geier A Z Gastroenterol; 2019 Apr; 57(4):508-517. PubMed ID: 30965381 [TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies. Agyapong G; Dashti F; Banini BA Ann N Y Acad Sci; 2023 Aug; 1526(1):16-29. PubMed ID: 37400359 [TBL] [Abstract][Full Text] [Related]
15. [Introduction to the APASL clinical guidelines on the management of metabolic-associated fatty liver disease]. Shi YW; Xiao QQ; Fan JG Zhonghua Gan Zang Bing Za Zhi; 2020 Nov; 28(11):915-917. PubMed ID: 33256275 [TBL] [Abstract][Full Text] [Related]
16. Emerging Gastrointestinal and Liver Diseases in Asia Pacific: Implications to Health Care in the Region (World Gastroenterology Organization: Asian Pacific Association of Gastroenterology Distinguished Global Lecture 2015). Goh KL J Clin Gastroenterol; 2017 Jul; 51(6):479-485. PubMed ID: 28591070 [TBL] [Abstract][Full Text] [Related]
17. Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis. Noureddin M; Jones C; Alkhouri N; Gomez EV; Dieterich DT; Rinella ME; Gastroenterology; 2020 Nov; 159(5):1985-1987.e4. PubMed ID: 32763241 [No Abstract] [Full Text] [Related]
18. Nonalcoholic Fatty Liver Disease: An Expanding Health Care Epidemic. Bernstein DE Clin Liver Dis; 2018 Feb; 22(1):xiii-xiv. PubMed ID: 29128064 [No Abstract] [Full Text] [Related]
19. Nonalcoholic Fatty Liver Disease and Incident Cardiac Events: The Multi-Ethnic Study of Atherosclerosis. Zeb I; Li D; Budoff MJ; Katz R; Lloyd-Jones D; Agatston A; Blumenthal RS; Blaha MJ; Blankstein R; Carr J; Nasir K J Am Coll Cardiol; 2016 Apr; 67(16):1965-6. PubMed ID: 27102512 [No Abstract] [Full Text] [Related]